According to a new evidence review, PB272 (neratinib), which is currently under review by the US Food and Drug Administration (FDA), will “...likely be approved for the extended adjuvant treatment of HER2-positive early stage breast cancer.”
The report from Advera Health Analytics collates data from 11 clinical trials to assess the candidate breast cancer therapy in comparison with Herceptin (trastuzumab) and Tykerb (lapatinib).
PB272 is being developed by USA-based Puma Biotechnology (Nasdaq: PBYI). Herceptin is sold by Swiss giant Roche (ROG: SIX) and Tykerb (known as Tyverb in Europe) is sold by British firm GlaxoSmithKline (LSE: GSK).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze